Xeris Biopharma Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M |
| Operating income | $24.9M | -$33.6M | -$44.0M | -$81.9M | -$115.2M |
| Cash from operations | $28.6M | -$37.0M | -$47.0M | -$102.9M | -$95.5M |
| Capital expenditure | — | — | — | — | $1.1M |
| Free cash flow | — | — | — | — | -$96.6M |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $383.5M | $323.1M | $322.6M | $344.5M | $304.4M |
| Total liabilities | $369.8M | $352.7M | $329.4M | $299.3M | $209.1M |
| Total debt | $233.6M | $248.8M | $198.8M | $197.2M | — |
Shares outstanding 172.6M · Free float 92.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.